Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18739823 | 1.00 | TDP1 (0.35) | TDP1EPHX1KMT2ASIGMAR1TP53 | |
| SCHEMBL13282223 | 0.83 | TDP1 (0.36) | TDP1EPHX1KMT2ASIGMAR1TP53 | |
| SCHEMBL9911530 | 0.83 | PLG (0.48) | TDP1EPHX1KMT2ASIGMAR1MEN1 | |
| SCHEMBL12871182 | 0.83 | PLG (0.48) | TDP1EPHX1KMT2ASIGMAR1MEN1 | |
| SCHEMBL12674307 | 0.83 | TDP1 (0.36) | TDP1EPHX1KMT2ASIGMAR1TP53 | |
| SCHEMBL8057761 | 0.81 | TDP1 (0.35) | TDP1EPHX1KMT2ASIGMAR1TP53 | |
| SCHEMBL13999457 | 0.81 | TDP1 (0.44) | TDP1EPHX1KMT2ASIGMAR1PARP1 | |
| SCHEMBL27014678 | 0.81 | TDP1 (0.35) | TDP1EPHX1KMT2ASIGMAR1TP53 | |
| SCHEMBL12667395 | 0.81 | TDP1 (0.35) | TDP1EPHX1KMT2ASIGMAR1TP53 | |
| SCHEMBL20032107 | 0.80 | EPHX1 (0.42) | TDP1EPHX1KMT2ASIGMAR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392428-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392428-B2 | GLP-1 derivatives and uses thereof | GLP1R, GIPR, VIP | TDP1 4063/4885EPHX1 3312/4885KMT2A 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.